Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies

Enrica Marchi, Luca Paoluzzi, Luigi Scotto, Venkatraman E. Seshan, Jasmine M. Zain, Pier Luigi Zinzani, Owen A. O'Connor

Research output: Contribution to journalArticle

48 Scopus citations

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this